Thrombosis Journal最新文献

{"title":"Research advances on platelet glycoprotein VI in ischemic stroke.","authors":"Hanlu Xiang, Ke Ding, Fanqiang Meng, Mengjie Huo, Wentao Yao, Hebo Wang","doi":"10.1186/s12959-026-00859-4","DOIUrl":"10.1186/s12959-026-00859-4","url":null,"abstract":"<p><p>Atherosclerosis is one cause of ischemic stroke. Subcutaneous collagen is exposed when the fibrous cap of an atherosclerotic plaque ruptures. Platelets bind to collagen, leading to platelet activation, aggregation, and thrombus formation. So, antiplatelet agents play a crucial role in the prevention and treatment of ischemic stroke. Nowadays, widely used antiplatelet agents, like aspirin, clopidogrel, and ticagrelor, inhibit thrombus formation while interfering with normal hemostasis, thereby increasing the risk of bleeding. Therefore, there is an urgent need for an antiplatelet agent that can prevent pathological thrombus formation without increasing the risk of bleeding. Glycoprotein Ⅵ (GPⅥ) is a glycoprotein specifically expressed on megakaryocytes and platelets. In patients and mouse models with GPⅥ deficiency, collagen-induced platelet adhesion and aggregation were reduced, resulting in only a mild bleeding tendency. Further research has revealed that targeting GPⅥ can inhibit thrombus formation, reduce thromboinflammation, decrease ischemia-reperfusion injury, and improve neurological deficits. Importantly, targeting GPVI didn’t increase the risk of bleeding or resulted in only minor bleeding. Additionally, its combination with thrombolytic agents, endovascular treatment, or other antiplatelet agents has been proven to be safe and effective. However, Phase II/III trials of agents targeting platelet GPVI failed to demonstrate positive efficacy outcomes in the treatment of ischemic stroke. While GPVI remains a promising antiplatelet target with favorable preclinical and early-phase safety data, clinical efficacy has not yet been demonstrated. Therefore, this review summarizes the potential mechanisms of targeting GPⅥ for antiplatelet therapy and reviews the evidence supporting the benefits of targeting GPⅥ for the prevention, treatment, and prognosis of ischemic stroke. It also summarizes the latest research progress on anti-GPⅥ agents, aiming to bring greater therapeutic benefits to patients with ischemic stroke.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13151315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147532956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid renal salvage in acute renal vein thrombosis secondary to membranous nephropathy using large-bore mechanical thrombectomy.","authors":"Sanjay Dev Singh, Chye Chung Gan, Limi Lee, Muhammad Syafiq Idris, Ahmad Rafizi Hariz Ramli","doi":"10.1186/s12959-026-00858-5","DOIUrl":"10.1186/s12959-026-00858-5","url":null,"abstract":"<p><p>BACKGROUND: Renal vein thrombosis (RVT) is a rare but serious complication of nephrotic syndrome, particularly in primary membranous nephropathy. Acute RVT with renal impairment and inferior vena cava (IVC) extension carries a high risk of irreversible renal injury. Thrombolysis may be contraindicated due to bleeding risk. CASE PRESENTATION: We report a 56-year-old man who presented with acute left flank pain, gross hematuria, anemia, and acute kidney injury. Investigations revealed nephrotic-range proteinuria and positive anti-phospholipase A2 receptor antibodies, consistent with primary membranous nephropathy. Computed tomography demonstrated extensive left renal vein thrombosis extending into the infrarenal IVC. Due to active hematuria and severe anemia, thrombolysis was contraindicated. Large-bore mechanical thrombectomy using the FlowTriever system was performed with temporary caval protection, achieving complete thrombus removal and restoration of renal venous outflow without thrombolytics. Hematuria resolved immediately and renal function stabilized. CONCLUSION: Large-bore mechanical thrombectomy represents a safe and effective thrombolytic-free option for acute extensive RVT, particularly in nephrotic syndrome patients with high bleeding risk. Early restoration of renal venous outflow may facilitate renal salvage and prevent long-term renal impairment. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147532900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired factor V inhibitor masked by triple antithrombotic therapy presenting as severe gastrointestinal bleeding: a case report.","authors":"Le Yang, Xin Li, Cong Mai","doi":"10.1186/s12959-026-00857-6","DOIUrl":"10.1186/s12959-026-00857-6","url":null,"abstract":"<p><p>We report the case of a 77-year-old male with a history of coronary artery disease, on long-term dual antiplatelet therapy (DAPT) and edoxaban anticoagulation, who presented with severe gastrointestinal bleeding. Laboratory investigations revealed a profound acquired factor V deficiency due to the presence of factor V inhibitors. The patient was successfully treated with transfusion support, immunosuppressive therapy, and continuous renal replacement therapy (CRRT) for fluid management, leading to resolution of symptoms and normalization of coagulation parameters.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147521852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative inflammatory and coagulation biomarkers for predicting venous thromboembolism after lower limb fracture surgery.","authors":"Jing Tian, Lixin Cao, Ziyu Zhang, Guangyu Ren","doi":"10.1186/s12959-026-00855-8","DOIUrl":"10.1186/s12959-026-00855-8","url":null,"abstract":"<p><p>BACKGROUND: Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is a preventable but serious postoperative complication in patients with lower limb fractures. Despite prophylactic measures, incidence remains high due to the interplay of trauma, immobility, and systemic inflammation. Biomarkers such as D-dimer, C-reactive protein (CRP), interleukin-6 (IL-6),and neutrophil-to-lymphocyte ratio (NLR), along with clinical recovery parameters, may improve prediction but remain under-integrated in orthopedic trauma risk models. METHODS: A retrospective observational study was conducted in 106 patients undergoing surgical fixation for lower limb fractures between 2021 and 2024. All patients received risk-stratified VTE prophylaxis per Caprini score and institutional guidelines. Perioperative blood samples were collected preoperatively and on postoperative days 1, 3, and 5 to measure inflammatory, hematologic, and coagulation parameters. Clinical and surgical data, including ambulation timing and hospital stay, were recorded. VTE diagnosis was symptom-triggered and confirmed via Doppler ultrasonography or computed tomography pulmonary angiography (CTPA). Statistical analyses included logistic regression with odds ratio (OR), calibration testing, and receiver operating characteristic (ROC) analysis. RESULTS: Twenty-one patients (19.8%) developed VTE. Significant risk factors included advanced age, hypertension, femoral fractures, delayed ambulation, and prolonged hospitalization. Biomarkers such as CRP, IL-6, tumour necrosis factor-α (TNF-α), D-dimer, NLR, and fibrinogen were consistently higher in VTE patients, particularly on postoperative Day 3. Multivariate analysis identified age (OR 1.05, 95% CI 1.01–1.10), hypertension (OR 2.41, 95% CI 1.01–5.76), delayed ambulation (OR 3.26, 95% CI 1.22–8.70), and elevated D-dimer (OR 1.32, 95% CI 1.08–1.63) as independent predictors. ROC analysis demonstrated strongest performance for D-dimer [area under the curve (AUC) 0.78], while a combined biomarker model integrating D-dimer, CRP, IL-6, NLR, and fibrinogen improved discrimination [AUC 0.86, sensitivity 81.0%, specificity 79.5%, negative predictive value (NPV) 93.2]. Calibration plots and decision curve analysis confirmed good model performance. CONCLUSION: This study demonstrates that perioperative biomarkers, particularly when integrated with recovery parameters such as ambulation delay, enhance prediction of postoperative VTE in orthopedic trauma patients. While findings are exploratory due to limited events and symptom-triggered detection, the results highlight the translational potential of combined biomarker–clinical models. Development and external validation of trauma-specific nomograms are warranted to enable individualized prophylaxis and improve patient outcomes. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13137685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147514926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The complement factor B inhibitor iptacopan for relapsed and refractory immune thrombotic thrombocytopenic purpura.","authors":"Minran Zhou, Xiaoqing Li, Ran Wang, Hai Zhou, Yu Hou, Ping Qin, Sai Ma, Chunyan Chen","doi":"10.1186/s12959-026-00854-9","DOIUrl":"10.1186/s12959-026-00854-9","url":null,"abstract":"<p><p>BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy, classified as congenital TTP (cTTP) and immune TTP (iTTP). iTTP represents the most common clinical subtype, accounting for approximately 95% of cases. Primary clinical features include microangiopathic hemolytic anemia (MAHA), thrombocytopenia, neuropsychiatric symptoms, fever, and renal involvement. Reduced ADAMTS13 activity and dysregulation of the complement pathway contribute to the pathogenesis of iTTP. First-line therapy for newly diagnosed iTTP, comprising plasma exchange and corticosteroids, demonstrates reasonable efficacy. However, some patients experience disease relapse with suboptimal response to plasma exchange. These relapsed and refractory cases pose significant therapeutic challenges and are associated with an extremely poor prognosis and high mortality. CASE PRESENTATION: Here, we report a case of relapsed and refractory iTTP presenting with scleral icterus, thrombocytopenia, altered mental status, fever, and renal impairment. Despite initial treatment with plasma exchange, corticosteroids, ripertamab, and intravenous immunoglobulin, the patient’s condition deteriorated rapidly. Laboratory tests revealed elevated levels of the terminal complement complex (C5b-9) and complement factor Ba in the patient. Consequently, we initiated treatment with the complement inhibitor iptacopan, combined with plasma exchange, corticosteroids, and rituximab. The hemoglobin and platelet count increased significantly by Day 5. At the 5-week follow-up, ADAMTS13 activity, hemoglobin, and platelet counts had all normalised. CONCLUSIONS: This case is a preliminary observation. With biomarker evidence supporting alternative pathway activation (e.g., elevated Ba and sC5b-9), it reports for the first time the potential association of combined therapy involving plasma exchange, corticosteroids, rituximab, and iptacopan with rapid clinical improvement in a patient with relapsed and refractory iTTP. It provides initial experience for exploring complement alternative pathway inhibition as a potential adjunctive strategy for such patients. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13137537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147514883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of apixaban versus enoxaparin in gynecologic cancer patients undergoing open surgery: an open-label randomized controlled trial.","authors":"Soheila Aminimoghaddam, Arash Mohazzab, Roghayeh Pourali, Hoda Zendehdel","doi":"10.1186/s12959-026-00853-w","DOIUrl":"10.1186/s12959-026-00853-w","url":null,"abstract":"<p><p>BACKGROUND: Women undergoing surgery for gynecologic malignancies are at high risk for postoperative venous thromboembolism (VTE). Although subcutaneous enoxaparin is commonly used for prophylaxis, concerns about cost, self-injections, and adherence have prompted investigation of oral alternatives such as apixaban. In this clinical trial, we compared the safety and efficacy of apixaban versus enoxaparin for postoperative VTE prophylaxis in patients undergoing open surgery for gynecologic cancers. METHODS: In this single-center, randomized, open-label trial, 450 patients with confirmed gynecologic malignancies undergoing open abdominal surgery were allocated in a 3.5:1 ratio to receive either apixaban (2.5 mg orally twice daily) or enoxaparin (40 mg subcutaneously once daily) for 14–28 days. The primary outcomes were the incidence of VTE and major bleeding within 30 days post‑surgery, corresponding to the active prophylaxis period. Data were analyzed using intention-to-treat principles. RESULTS: No significant difference was observed in the baseline characteristics of the two study groups. Within 30 days, VTE occurred in 2.0% of patients in the apixaban group and 3.0% in the enoxaparin group (p = 0.891), confirming non-inferiority. Major bleeding events were significantly lower in the apixaban group (1.4%) compared to the enoxaparin group (9.0%) (p = 0.001). No other adverse effects were reported in any of the study groups. CONCLUSION: Apixaban demonstrated comparable efficacy and superior safety to enoxaparin for postoperative thromboprophylaxis in women undergoing open gynecologic cancer surgery. These findings support apixaban as a viable alternative to enoxaparin in this population. CLINICAL TRIAL NUMBER: IRCT20220211053991N1. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13011513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147504962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ischemic stroke despite therapeutic anticoagulation in eosinophilic fasciitis with compartment syndrome and deep vein thrombosis: a case report.","authors":"Jun He, Wenchao Guo, Haowu Tang, Chuanchong Zong, Xiaorui Jiang","doi":"10.1186/s12959-026-00856-7","DOIUrl":"10.1186/s12959-026-00856-7","url":null,"abstract":"<p><p>BACKGROUND: Eosinophilic fasciitis is a rare connective tissue disorder characterized by fascial inflammation and eosinophil infiltration. Thromboembolic complications in eosinophilic fasciitis are uncommon and poorly understood. We report a case that highlights the limitations of conventional anticoagulation in preventing eosinophil-mediated thrombosis. CASE PRESENTATION: A 60-year-old Chinese man presented with a 10-day history of progressive bilateral lower extremity swelling and pain. Laboratory investigations revealed severe hypereosinophilia and imaging revealed left lower-extremity deep vein thrombosis complicated by acute compartment syndrome. Despite therapeutic enoxaparin anticoagulation with documented hypocoagulable state on thromboelastography, the patient developed bilateral lacunar infarctions on day 7. Bone marrow aspiration excluded hematological malignancies, and fascial biopsy confirmed eosinophilic fasciitis. Following glucocorticoid therapy initiation, eosinophil levels normalized with complete resolution of symptoms. No recurrence of thrombotic events was observed during one-year follow-up. CONCLUSION: This case highlights that eosinophilic fasciitis-associated hypereosinophilia can induce a prothrombotic state resistant to conventional anticoagulation, likely through eosinophil granule protein-mediated mechanisms. Early recognition and prompt glucocorticoid therapy, rather than anticoagulation alone, may be critical for preventing life-threatening thromboembolic complications in eosinophilic fasciitis. This report adds to the limited literature on thrombotic manifestations of eosinophilic fasciitis and underscores the need for heightened clinical vigilance and a shift in therapeutic paradigm toward early immunosuppression. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147514878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multi-biomarker nomogram based on miR-155-5p and NETs predicting deep vein thrombosis risk stratification.","authors":"Shun Xiao, Kun Zhang, Zong-Gang Zhao, Bing Liu","doi":"10.1186/s12959-026-00839-8","DOIUrl":"10.1186/s12959-026-00839-8","url":null,"abstract":"<p><p>OBJECTIVE: Deep vein thrombosis (DVT) represents a major thrombo-inflammatory disorder with substantial diagnostic challenges. Emerging evidence implicates that neutrophil extracellular traps (NETs) and miR-155 are involved in thrombosis, yet their integrated predictive utility remains unexplored. The aim of this study is to develop and validate a multi-biomarker nomogram incorporating miR-155-5p and NETs markers for individualized risk stratification of DVT. METHOD: A total of 110 patients diagnosed with DVT by angiography from January 2022 to December 2023 were selected and matched with 61 healthy subjects. The differences and correlations of serum miR-155-5p and NETs markers between the two groups were compared. Multivariate logistic regression identified independent predictors, and a predictive nomogram was constructed. Internal validation was performed using bootstrap resampling. Discriminative capacity, calibration, and clinical utility were assessed by ROC analysis, calibration curve, and decision curve analysis (DCA). RESULTS: The serum miR-155-5p and NETs levels of the two groups were analyzed, and the results showed a significant enhancement in serum miR-155-5p and NETs levels in DVT patients compared to healthy subjects. The study further analyzed the correlation between serum miR-155-5p and related NETs markers, and found that serum miR-155-5p was positively correlated with MPO-DNA (r = 0.480) and citH3 (r = 0.494). Logistic analysis indicated that miR-155-5p (OR = 3.339), citH3 (OR = 2.602), and D-dimer (OR = 2.701) miR-155-5p (OR = 3.339), citH3 (OR = 2.602), D-dimer (OR = 2.701), Neutrophil-to-Lymphocyte Ratio (NLR) (OR = 1.582), and MHR (OR = 1.117) were independent risk factors for the occurrence of DVT. The integrated nomogram demonstrated excellent discriminative performance (AUC = 0.955) and robust calibration with minimal overfitting. DCA confirmed significant clinical utility across a broad threshold probability range. CONCLUSIONS: We developed and internally validated a novel multi-biomarker nomogram that integrates miR-155-5p, NETs marker citH3, and inflammatory indices, providing a robust, quantitative tool for individualized DVT risk prediction. This model offers superior discriminative capacity and clinical applicability, warranting external validation for translation into clinical practice. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13123148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147481738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of novel inflammation markers derived from high-sensitivity C-reactive protein with anemia: a cross-sectional study based on NHANES 2015-2018.","authors":"Jing Peng, Li Wan, Jing Tan, Linli Zeng","doi":"10.1186/s12959-026-00851-y","DOIUrl":"10.1186/s12959-026-00851-y","url":null,"abstract":"<p><p>BACKGROUND: This study aimed to investigate the associations of the high-sensitivity C-reactive protein to high-density lipoprotein cholesterol ratio (HCHR) and the high-sensitivity C-reactive protein to lymphocyte ratio (HCLR) with anemia in the general population. METHODS: A cross-sectional analysis was conducted using data from 8638 adults enrolled in the National Health and Nutrition Examination Survey (NHANES) 2015–2018. Anemia was defined according to the World Health Organization (WHO) criteria. HCHR and HCLR were calculated based on laboratory measurements. Multivariable logistic regression models were applied to estimate the associations between HCHR, HCLR, and anemia. Subgroup analyses and smooth curve fitting were performed to assess effect modification and potential nonlinear relationships. Sensitivity analyses were also performed to assess the robustness of the results. RESULTS: Among the 8638 participants, 930 individuals had anemia. Compared with non-anemic participants, those with anemia had significantly higher median levels of HCHR (p < 0.001) and HCLR (p < 0.001). In fully adjusted models, higher HCHR (OR = 1.007, 95% CI: 1.002–1.011, p = 0.012) and HCLR (OR = 1.027, 95% CI: 1.013–1.042, p = 0.004) were independently associated with an increased risk of anemia. Compared with the lowest quartile, participants in the highest quartile of both HCHR and HCLR had significantly greater odds of anemia (P for trend < 0.05). Subgroup analyses confirmed the consistency of the associations between HCHR, HCLR, and anemia. Smooth curve fitting revealed nonlinear relationships between HCHR, HCLR, and anemia risk. CONCLUSION: Higher HCHR and HCLR were significantly associated with an increased risk of anemia among U.S. adults, underscoring the potential utility of inflammation-based composite biomarkers in anemia risk stratification. Nevertheless, further prospective studies are warranted to confirm causality and evaluate clinical applicability. CLINICAL TRIAL NUMBER: Not applicable. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13104406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147469206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of the photoacoustic detection of haemophilia-related microbleeds: a preclinical study using isolated pig limbs.","authors":"Asuka Sakata, Yusuke Inagaki, Naoto Sato, Ryuhei Ogawa, Yuya Mawarikado, Kimiko Shimizu, Kohei Tatsumi, Tetsuhiro Soeda, Akira Kido, Midori Shima, Keiji Nogami","doi":"10.1186/s12959-026-00852-x","DOIUrl":"10.1186/s12959-026-00852-x","url":null,"abstract":"<p><p>BACKGROUND: Recent advancements in haemophilia treatment have dramatically reduced the frequency of symptomatic bleeding. However, minor, asymptomatic bleeding may contribute to the progression of joint damage and decrease quality of life. Detecting small amounts of blood with minimal flow is difficult using existing testing methods, necessitating the development of new diagnostic approaches. AIM: To determine whether tiny amounts of blood injected subcutaneously, intramuscularly, and intra-articularly can be detected in a pig to assess the feasibility of detecting microbleeds in people with haemophilia. METHODS: Pig whole blood was injected subcutaneously, intramuscularly, and intra-articularly into the isolated hind limbs of pigs. Photoacoustic imaging (PAI) was performed using an Acoustic X device (CYBERDYNE INC, Tsukuba, Japan) to detect blood signals. RESULTS: Following the injection of 200 µL of blood, conventional ultrasound imaging revealed no discernible changes, such as echo-free spaces. Conversely, on PAI, a signal indicating the presence of blood was detected. CONCLUSIONS: We have demonstrated that even very small amounts of nonflowing blood injected into the subcutaneous tissue, muscle, and joint of the hind limbs of pigs can be detected using PAI. We believe that the results of this study show the potential of this technique for detecting microbleeds in people with haemophilia. TRIAL REGISTRATION: Not applicable. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13104323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147469197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}